Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levafetamine

Drug Profile

Levafetamine

Alternative Names: C 105; L-alpha-methylphenethylamine; L-amfetamine; L-amfetamine sulfate; L-amphetamine; L-amphetamine sulfate; Levamfetamine; Levoamphetamine

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Brown University; Sention
  • Developer Cognition Pharmaceuticals
  • Class Amphetamines; Antidementias; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants; Neurotransmitter modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cognition disorders

Most Recent Events

  • 19 Dec 2008 Interim efficacy and safety data from the phase II, NCT00529581 trial in patients with cognitive impairment due to multiple sclerosis (Cognition disorders) released by Cognition Pharmaceuticals
  • 30 Apr 2008 Cognition Pharmaceuticals completes the phase II, NCT00529581 trial for cognitive impairment in patients with multiple sclerosis (Cognitive disorders) in USA
  • 19 Jan 2005 Sention completes phase I trials in Cognitive disorders
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top